Supplement Manufacturing Agreement Red Flags: 12 Clauses to Catch Before You Sign

This guide is written for founders who are about to sign their first (or fifth) supplement contract manufacturing agreement and want a checklist they can actually use. It is not legal advice — please retain a contract-manufacturing-experienced lawyer for any agreement above $25,000 in annual spend or any custom-formula deal. What this guide does give you is the redlines we see come up most often, in plain language, with the exact wording shifts that turn a risky clause into a clean one.

Most founders evaluate manufacturers on three things: per-unit price, MOQ, and lead time. Those are the easy numbers — they show up on the first email and they sound comparable across quotes. The agreement is where the actual cost lives. A $0.40-cheaper per-unit price means nothing if the contract lets the manufacturer raise the price after your first run, hold your formula on exit, or cap their liability at 5% of the value of a defective batch.

The hard truth: the manufacturers with the most aggressive boilerplate are usually the manufacturers who win on price. They make up the margin on contract terms that put risk back on you. Reviewing the agreement carefully is not paranoia — it is the most leveraged 60 minutes you will spend on the entire launch.

This is the single most expensive clause in the agreement. If you paid for custom R&D — prototyping, stability testing, substantiation work — the formula must be assigned to you in writing. The dangerous wording: "Manufacturer retains all rights to all formulations developed in connection with this Agreement." The clean wording: "All Formulas, Specifications, and Substantiation files developed for Brand under this Agreement, including any work-for-hire R&D, shall be the sole and exclusive property of Brand."

For more on the IP economics across manufacturing models, see Dropship vs Private Label vs Custom Supplement Manufacturing.

MOQ should be a fixed unit count per production run — for example, 2,000 units per SKU per run. Two patterns to watch for:

• Annual minimum-spend clauses: "Brand commits to a minimum of $X in production spend per calendar year." This shifts demand risk entirely to you. If the SKU underperforms, you owe the shortfall.
• Unilateral MOQ escalation: "Manufacturer reserves the right to adjust minimum order quantities based on production capacity." Translation: they can raise MOQ at renewal and you have no recourse.

The clean version: MOQ is fixed per SKU per run, any changes require 60 days' written notice and your acceptance, and there is no annual minimum-spend commitment unless you are explicitly trading volume for price.

Every production run must be tied to a written Quality Assurance release. The agreement should require, in writing, that before goods ship:

• A signed Certificate of Analysis (COA) from an ISO 17025–accredited lab covering identity, potency, microbial limits, and heavy-metal results (USP <232> for dietary supplements).
• A unique batch / lot number assigned to the run and printed on every unit, traceable to the raw material lots used.
• A retain sample (typically 2x the amount needed for re-testing) held by the manufacturer for the shelf life of the product plus one year.
• A QA-signed release document stating the batch meets specification, with the QA person's name and date.

The red-flag version of this clause is silence — no mention of COAs, no mention of retain samples, no QA release language. If the agreement does not require it, you will not get it consistently. For the full QA paper trail Peakfinity Labs ships with every batch, see our Quality program and our guide to GMP-certified supplement manufacturing.

"Estimated lead time: 6–8 weeks." That sentence, with no remedy, is responsible for more missed launches in this industry than any other line in any agreement. A clean lead-time clause has three components:

• A defined production window in calendar days from a defined start point ("28–42 calendar days from approved label artwork, approved formula, and cleared deposit").
• A clear definition of 'approved' — what artifact, signed by whom, triggers the clock.
• A remedy if the window is missed — credit on next run, percentage rebate, or right to cancel without penalty. Pick at least one.

Manufacturers will resist defined remedies because they shift risk back. Hold the line — without a remedy, the lead time is a marketing number, not a contract term.

Three flavors of lock-in to watch for:

• Exclusivity: "Brand agrees to manufacture all dietary supplement products exclusively with Manufacturer for the term." Almost never acceptable for a founder. If a manufacturer wants exclusivity, they should pay for it (capacity commitments, price guarantees, R&D credits).
• Non-compete on category: "Brand agrees not to manufacture similar products with any other supplement manufacturer for X months after termination." Reasonable only if narrowly scoped to a specific custom formula they developed and paid for.
• 'Most Favored Customer' (MFC) clauses pointing the wrong way: the manufacturer requires you to give them MFC pricing on any retail deal you sign. Hard pass — your retail pricing is yours to set.

Some price flexibility is reasonable — raw material costs do move, and locking a manufacturer into a fixed price for years isn't realistic. What's not reasonable is open-ended language. Watch for:

• "Pricing subject to change based on market conditions" with no notice period and no cap.
• Automatic pass-through of any raw material increase, even routine ones, without aggregation or a threshold.
• No price-stability window — you should have at least 90 days' written notice on any increase, and ideally an annual cap (e.g., no more than X% per year except for documented commodity moves above Y%).

You should have the contractual right to:

• Receive a batch COA for every production run, automatically, before goods ship.
• Request the full batch record (raw material lots, in-process checks, QA sign-offs) for any batch within a reasonable timeframe.
• Conduct a facility audit, either in person or via a third-party auditor, with reasonable notice (typically once per year).
• Receive documentation that survives the relationship — meaning if you exit, you keep historical batch records for the products you sold under your brand.

"All quality records are property of Manufacturer and are not available for review" is a hard no. Retailers, FDA, and your own product-liability insurer can all require these documents. If you can't get to them, you can't run a serious brand.

Boilerplate liability caps in vendor agreements are often "1× of fees paid in the preceding 3 months." That works for SaaS. It does not work for physical product manufacturing. A defective $40,000 production run capped at $5,000 means the manufacturer's worst case is refunding your fees while you absorb the inventory loss, the customer refunds, and the recall cost.

What to push for:

• Cap at least equal to the value of the affected batch at minimum.
• Uncapped carve-outs for manufacturer negligence, willful misconduct, IP infringement, and breach of confidentiality.
• A contractual requirement that the manufacturer maintain product liability insurance (typically $2M+ per occurrence) with Brand named as an additional insured, with proof of insurance provided annually.

If a batch is defective and a recall is required, who pays for what? The agreement should answer:

• Defect at manufacturer's fault (out-of-spec, contamination, mislabeling due to manufacturer error): manufacturer covers replacement product, recall logistics, customer refunds, and FDA reporting costs.
• Defect at Brand's fault (Brand-supplied artwork error, Brand-specified ingredient issue): Brand covers those costs.
• Shared / ambiguous causes: allocation method defined in advance, typically via root cause analysis with a neutral third party if disputed.
• Indemnification language: each party indemnifies the other for losses caused by its own breach, with named carve-outs for third-party IP claims and regulatory actions.

See our compliant supplement guide for related FDA labeling and recall context.

A clean exit clause is the single best protection a founder has. It should include:

• Termination for convenience with 30–90 days' written notice, no penalty.
• Termination for cause with cure period (typically 30 days) for material breaches.
• Tech-pack release on termination: manufacturer must deliver, within 30 days of termination, all Brand-owned IP — formula, specifications, label artwork files, substantiation files, and historical batch records.
• Inventory and component disposition: Brand can purchase any remaining finished goods, work-in-process, and Brand-specific components (labels, cartons, custom bottles) at agreed pricing.
• No 'evergreen' renewal that auto-extends the term without affirmative consent.

"100% payment due upon order placement, no refunds, no exceptions" is common — and it puts every dollar of cash risk on you before any QA work happens. Reasonable structures:

• 50% on order placement / 50% on QA release is the most founder-friendly standard.
• 30/40/30 (deposit / mid-production / on release) is also common for larger runs.
• Net-30 on QA release for established relationships with strong credit history.

What you want to avoid: 100% upfront with no refund language and no QA release tied to final payment. That structure removes any incentive for the manufacturer to fix issues quickly, because they already have your money.

For a US founder working with a US manufacturer, jurisdiction should be a US state (typically the state where the manufacturer is based, which is a reasonable concession). For offshore manufacturers, the calculation changes — a clause requiring arbitration in Singapore, Mauritius, or another offshore venue is technically valid but practically unenforceable for a small brand. Three watch-outs:

• Offshore arbitration with fees that exceed the value of most disputes a small brand would bring.
• Mandatory arbitration with class-action waiver — common and usually fine for B2B, but check the venue and rules.
• Choice-of-law in a jurisdiction with weak supplement-industry case law or weak enforcement of supply-chain contracts.

For more on US-vs-overseas manufacturer trade-offs that touch this clause, see US Manufacturer vs Overseas for Supplements and India vs China Supplement Manufacturing.

Use this as the final pass before signing any supplement contract manufacturing agreement.

• ☐ Formula IP ownership is written, explicit, and assigns paid-for custom work to Brand.
• ☐ MOQ is fixed per SKU per run, no annual minimum-spend, no unilateral escalation rights.
• ☐ COA from an ISO 17025–accredited lab is required before every shipment, with batch number, retain sample, and QA release.
• ☐ Lead time is a defined window with a clear start trigger and at least one remedy if missed.
• ☐ No exclusivity, narrow (or removed) non-compete, no "Most Favored Customer" obligations on Brand.
• ☐ Price-change clause has a notice period, a documentation requirement, and an annual cap or stability window.
• ☐ Brand has the right to receive batch records, request audits, and retain historical quality documentation after termination.
• ☐ Liability cap is at least the value of one production run, with uncapped carve-outs for negligence, willful misconduct, and IP claims.
• ☐ Recall and indemnification responsibilities are allocated by root cause, with manufacturer insurance verified and Brand named as additional insured.
• ☐ Termination for convenience is allowed with reasonable notice, and the manufacturer must release the tech pack and Brand-owned IP on exit.
• ☐ Payment terms tie final payment to QA release, not order placement.
• ☐ Jurisdiction and dispute resolution are in a venue you can actually enforce in.

When you receive a draft agreement, send these questions back before redlining. The answers tell you how flexible the manufacturer actually is — and the speed of their response tells you what working with them will feel like.

• Send by email: "Can you confirm in writing that any custom formula work paid for by us is assigned to us, including derivatives of your base formulas that we commission?"
• Send by email: "What is the production window from approved label and cleared deposit, and what is the remedy if it's missed?"
• Send by email: "Confirm that a COA from an ISO 17025–accredited lab covering identity, potency, microbial, and heavy-metal results is issued for every batch before shipment, and that a retain sample is held for shelf life plus one year."
• Send by email: "What is the liability cap, and will you carve out manufacturer negligence, willful misconduct, and IP infringement from the cap?"
• Send by email: "If we terminate, do you release our formula, label files, and batch records, and on what timeline?"
• Send by email: "Are payment terms 50% on PO and 50% on QA release, or what alternative structure ties final payment to release?"

A manufacturer who answers all six in plain English within 48 hours is a different operational partner from one who hedges or routes everything through "let's discuss on a call." Both responses are data.

For reference, here's how Peakfinity Labs' standard MSA addresses each of the twelve red flags. We share this because the best way to negotiate any agreement is to have a benchmark.

If a manufacturer's draft is materially weaker than the table above on three or more rows, that is the signal to redline hard or shortlist a different partner. For a side-by-side on partner selection, see What Makes a Good Contract Manufacturer for Small Ecommerce Brands.